July 15, 2015

Pressure BioSciences' PCT Platform a Key Workflow Component in Study to Discover Potential Biomarkers and Underlying Pathways in the Emergence and Progression of COPD-Associated Lung Cancer

Unique Marketing Campaign Helps Attract a 10-fold Increase in Prospective Client Visits to View Company's Products at Major Scientific Conference

SOUTH EASTON, Mass., July 15, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that data on the identification of multiple molecular pathways in COPD-associated lung cancer were presented at the recent American Society for Mass Spectrometry ("ASMS") annual conference. To maximize the number of protein expression differentials that could be revealed, PCT was the method of choice for cell lysis and membrane disruption, two critical sample preparation steps in the study. Lead author and study presenter was Dr. Brian Sandri of the University of Minnesota ("UMN"). Co-authors included other scientists from UMN, as well as from the Mayo Clinic (Rochester, MN), the Karolinska Institutet (Solna, Sweden), and the Center for Mass Spectrometry and Proteomics (St. Paul, MN).

Chronic Obstructive Pulmonary Disease ("COPD") is a leading cause of death in the United States. It is a serious lung condition and a key risk factor for lung cancer, independent of smoking. There is no cure and no way to reverse the damage done by the condition. Unfortunately, the reasons that some patients with COPD progress to lung cancer are not known. The goal of the study was to identify molecular pathways involved in the development and progression of COPD-associated lung cancer. Illumination of these pathways could potentially contribute towards development of improved therapeutic strategies for patients with COPD.

Mr. Richard T. Schumacher, President and CEO of PBI, said: "In their presentation, Dr. Sandri and colleagues reported on the identification of several differentially expressed lung tissue proteins that may be related to the development and/or progression of COPD-associated lung cancer, and identified several biochemical pathways in which these putative biomarkers are known to be active. These are exciting and potentially important findings."

Mr. Schumacher continued: "For their study, the authors developed a highly customized workflow, including extensively developed sample preparation, sample analysis, and data reduction capabilities. We are pleased that this workflow included PCT as the sample preparation method of choice, as the authors had previously shown that PCT could extract substantially more proteins from lung tissue than other extraction methods."

Dr. Nate Lawrence, Vice President of Marketing and Sales, said: "ASMS 2015 was an extremely successful meeting for PBI. The role of PCT in helping to achieve significantly superior research results was highlighted in several presentations from well-regarded research scientists, including these intriguing results on COPD-related lung cancer from Dr. Sandri and his colleagues."

Dr. Lawrence continued: "In addition to having a booth on the exhibition floor during the day, the Company had for the first time a hospitality suite each evening, where we showcased all of PBI's high pressure instruments and consumables for sample preparation. As a past exhibitor at ASMS, we have typically met with 75-100 scientists at our exhibit booth throughout the meeting, as these potential customers and collaborators are often available only between scientific sessions. This year, with the PBI hospitality suite open each evening, and propelled by a unique marketing campaign, we were able to show our PCT product line, including the newly released PCT-HD, micro-Pestle, and Barozyme HT-48 Systems, to over 800 visitors, about 10x more than any previous year."

Dr. Lawrence concluded: "The hospitality suite provided a relaxed venue where researchers could evaluate our PCT Platform and discuss their specific applications and requirements for mass spectrometry sample preparation with PBI scientists. We anticipate that a number of these scientists will become new customers of the PCT Platform, and we look forward to the inclusion of PCT in their presentations at upcoming ASMS meetings.**"**

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are

subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, and in other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:	
Richard T. Schumacher, President & CEO	Pressure BioSciences, Inc.
Nate Lawrence, Vice President of Sales & Marketing	(508) 230-1828 (T)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-pct-platform-a-key-workflow-component-in-study-to-discover-potential-biomarkers-and-underlying-pathways-in-the-emergence-and-progression-of-copd-associated-lung-cancer-300113606.html

SOURCE Pressure BioSciences, Inc.